Remove Data Remove Patients Remove Safety Remove Sleep
article thumbnail

Survey Reveals Almost Half of Canada’s MMJ Patients Reduced Their Alcohol and Opioid Consumption

Veriheal

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

article thumbnail

US Hemp Roundtable: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION

Cannabis Law Report

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Their participation strengthened the statistical reliability of both the liver safety results and achieved statistical relevance for both sleep and testosterone results.

Safety 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sapphire Medical Clinics present new data from the UK Medical Cannabis Registry at the 31st Annual International Cannabinoid Research Society Symposium on Cannabinoids

Cannabis Law Report

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). Patient-reported outcomes. PROGRAMME.and.ABSTRACTS. Improved quality of life.

article thumbnail

US Hemp Round Table: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION

Cannabis Law Report

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The second cohort included an additional 222 individuals taking CBD produced by an additional five companies.

Safety 52
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Patients who suffer from epilepsy , which affects some 3.4 million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Researchers Analyzed Survey Results from 280 Epilepsy Patients.

article thumbnail

Sapphire Medical Clinics expands patient access to cheapest medical cannabis fees in UK

Cannabis Law Report

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52